Recruiting

NCT Number: NCT06578702

Evaluation of Intermittent Triple Therapies in Real Life

The strategy of intermittent triple therapy for people living with HIV was validated in France following the randomized clinical trial QUATUOR. There is little data in real life, as shown in the meta-analysis of Parienti JJ et al.

Currently this strategy is proposed by some teams in France, but is not recommended internationally.

The research hypothesis is that intermittent treatment is an effective and safe option in a therapeutic lightening strategy in people living with HIV People living with HIV adults followed in Strasbourg who have benefited from intermittent treatment The expected results will consist of an improvement in knowledge on the efficacy and tolerance of this therapeutic strategy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

HIV Infections Blood-Borne Infections Communicable Diseases Genital Diseases Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service Le Trait d'Union - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Axel URSENBACH, MD

CONTACT

[email protected]

33 3 69 55 13 52

Axel URSENBACH, MD

PRINCIPAL_INVESTIGATOR

Baptiste Hoellinger, MD

SUB_INVESTIGATOR

Céline Melouno, MD

SUB_INVESTIGATOR

David Rey, MD

SUB_INVESTIGATOR

Paul Klee, MD

SUB_INVESTIGATOR

Thomas Lemmet, MD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult subject (≥ 18 years old)
Living with HIV monitored at the Trait d'Union/Infectious Diseases department in Strasbourg
Having benefited from intermittent triple therapy between 01/01/2017 and 31/01/2024

Exclusion criteria

Subject (and/or their legal representative if applicable) having expressed their opposition to the reuse of their data for scientific research purposes.

Treatment and study plan

Primary outcomes

Evaluation of HIV viral load

Time frame: 48 weeks after reduction of the HIV viral load

Study contacts

Contact information is provided by the study sponsor or research team.

Axel URSENBACH, MD

CONTACT

[email protected]

33 3 69 55 13 52

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: ETRIVIE

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Aug 29, 2024
Registry last updated: Aug 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting